Camargo Invests in High-Level IT System To Increase Accessibility and Preserve Client Data
Camargo Pharmaceutical Services recently completed an extensive IT system update
Camargo Pharmaceutical Services
recently completed an extensive IT system update to offer its clients improved data availability, security, storage and redundancy. The new system is an important investment to Camargo’s infrastructure, allowing the full-service development partner to add value for its clients.
With these improvements, Camargo provides each of its national and international clients with an individual website including large-scale data storage availability, document management with version control, a superior level of security with minimal interruptions and 24/7 rapid access. The system also includes data retention and preservation for at least 20 years — exceeding the FDA’s and global regulatory agencies’ minimum data preservation requirements.
“Implementing enhanced data access and storage capacity are examples of the strides Camargo is making to broaden our service line, support our clients from concept through commercialization and grow our client base internationally,” said Jim Beach, chief operating officer for Camargo. “Data and its preservation are the lifeblood of product development programs and this new system supports our critical role as stewards of our clients’ data.”
To learn more about Camargo’s service offerings, visit
camargopharma.com
.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
